🟢 VERA is trading 5% up today as investors position ahead of FDA decision on atacicept

VERA is trading 5% up at $42.14 as investors position ahead of a key FDA decision for its IgA nephropathy treatment, atacicept.

• The Biologics License Application (BLA) for atacicept has been granted Priority Review by the FDA, signaling an expedited assessment process.
• The PDUFA target action date is set for July 7, 2026, making the current regulatory progress a significant catalyst for the stock.